
Cough: A Typical Study
A customer conducted a phase IIb Clinical trial to investigate the efficacy and safety of an investigational medicinal product in patients with refractory and/or unexplained chronic cough. By using the VitaloJAK which has an accuracy rating of 99.9%, the sponsor was provided with reliable, quality data for their trial’s primary and secondary outcome measures for cough.